Apr 30, 2020
Switching Patterns Among Relapsing-Remitting Multiple Sclerosis: Genentech's Ocrevus on the Rise, Biogen's Tecfidera Declines, and Teva's Copaxone Remains Strong, According to Spherix Global Insights
Apr 20, 2020
HTA in Major Pharma Industries, 2020 - Includes Profiles of Daratumumab (Darzalex), Tildrakizumab (Ilumya), Durvalumab (Imfinzi), Abemaciclib (Verzenio), and Ocrelizumab (Ocrevus)
Apr 09, 2020
Roche's Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis' Mayzent and Ofatumumab May Threaten the Brand's Long-Term Dominance
Mar 10, 2020
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's Vumerity Begins to Chip Away at the Company's Own Tecfidera
Feb 11, 2020
Overall Share of Ocrevus Remains Stable Among Recent New Start Patients, Yet Genentech's Efforts to Increase First-Line Use Appears to be Paying Off in the Dominant Relapsing-Remitting Multiple Sclerosis Subgroup
Oct 07, 2019
Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months
Jul 16, 2019
Ublituximab Drug Overview 2019: An Anti-CD20 Monoclonal Antibody, Currently in Late-Stage Trials Across a Range of Hematological and Neurological Indications
Jun 26, 2019
With Novartis' Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono's Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure
May 28, 2019
EMD Serono's Mavenclad Edges Past Novartis' Gilenya in the Recent Switch Segment of Canada's Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
Apr 10, 2019
Preferential First-Line Use of Biogen's Tecfidera and Continued Uptake of Merck KGaA's Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year
Feb 04, 2019
Global Multiple Sclerosis Dynamic Market 2018-2026: Gilenya Sales will be Affected by Erosion of Generics and Launch in the Market of the Second Generation of S1P Receptor Modulators
Mar 27, 2018
Uptake of Merck KGaA's Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals
Nov 07, 2017
Decision Resources Group Projects G7 Sales Of The Multiple Sclerosis Market To Exceed $25 Billion In The Next Decade